Holen Sie sich die Stockscreener-App
5.97
2.45%
-0.15
Handel nachbörslich:
6.02
0.05
+0.84%
Schlusskurs vom Vortag:
$6.12
Offen:
$6.22
24-Stunden-Volumen:
1.47M
Relative Volume:
0.95
Marktkapitalisierung:
$339.04M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.4526
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
-3.24%
1M Leistung:
-16.74%
6M Leistung:
+21.59%
1J Leistung:
+72.05%
1-Tages-Spanne:
$5.97
$6.303
1-Wochen-Bereich:
$5.89
$6.62
52-Wochen-Spanne:
$2.10
$9.10
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Vergleichen Sie VSTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.97 | 339.04M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN
ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech
Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria
Transcript : Verastem, Inc.Special Call - marketscreener.com
What's Going On With Verastem Oncology Stock On Monday? - Benzinga
Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace
Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria
(VSTM) Proactive Strategies - news.stocktradersdaily.com
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - sharewise
Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News - GuruFocus
Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
Verastem stock soars to 52-week high, hits $8.5 By Investing.com - Investing.com South Africa
Verastem stock soars to 52-week high, hits $8.5 - Investing.com Australia
US High Growth Tech Stocks to Watch in May 2025 - simplywall.st
VSTM Up As NDA For Ovarian Cancer Combo Gets FDA's Priority Review Tag - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail
Verastem (VSTM) Stock Price, News & Analysis - MarketBeat
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC - Yahoo Finance
Verastem Announces Positive RAMP 205 Trial Results - TipRanks
Verastem Oncology Announces Positive Updated Results from RAMP 2 - GuruFocus
Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News - GuruFocus
Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate - marketscreener.com
Verastem Oncology reports high response in pancreatic cancer trial By Investing.com - Investing.com Canada
Verastem Oncology reports high response in pancreatic cancer trial - Investing.com
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - FinancialContent
Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges - Investing.com
Verastem Inc (VSTM) Has Recovered 72.4% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Verastem CFO sells $90,592 in stock By Investing.com - Investing.com Nigeria
Tempus and Verastem partner on ovarian cancer diagnostic test By Investing.com - Investing.com South Africa
Verastem CFO sells $90,592 in stock - Investing.com
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - 01net
Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - marketscreener.com
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment - Stock Titan
The Manufacturers Life Insurance Company Makes New $74,000 Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World
(VSTM) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Stifel Financial Corp Grows Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World
11,402 Shares in Verastem, Inc. (NASDAQ:VSTM) Purchased by Voya Investment Management LLC - Defense World
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem: Q1 Earnings Snapshot - Greenwich Time
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.92%
7.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):